Prolonged T-cell deficiency induced by alemtuzumab is known to facilitate opportunistic infections and specifically to impair recovery of EBV-specific CD8+ T lymphocytes making the patient vulnerable for EBV-driven lymphoproliferation. Here, CD8A is linked to congenital T-cell immunodeficiency.